Please wait while we open this resource.
K
Clinical reviews
EPLONTERSEN FOR TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
CARDIO-TTRansform Investigators
PDF202412 pages391 KB
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a life-threatening condition characterized by the accumulation of misfolded transthyretin proteins in the heart. The study evaluates the efficacy of eplontersen, which aims to reduce the production of hepatic TTR. This phase 3 trial involved a double-blind methodology, comparing eplontersen to a placebo over a period of 140 weeks, focusing on cardiovascular outcomes.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology